Compumedics Limited (CMP) AI Stock Analysis

• Market Cap: AU$72.08M
• Dividend Yield: N/A
• Average Volume (3M): 91.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: 2.23%
• EPS Growth: -263.16%
• Country: AU
• Employees: 155
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 192,217,900
• 10 Day Avg. Volume: 145,264
• 30 Day Avg. Volume: 91,257
• PEG Ratio: -0.14
• Price to Book (P/B): 2.12
• Price to Sales (P/S): 0.91
• P/FCF Ratio: 99.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.50
• Price Target Upside: 38.89% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: AU$0.50 ▲(38.89% Upside)

Compumedics Limited's overall stock score reflects a mixed financial performance with significant challenges in profitability and cash flow management. While revenue growth is a positive aspect, the negative net profit margin and poor cash flow generation weigh heavily on the score. Technical analysis provides a neutral outlook, with stable price trends but no strong momentum. Valuation is a concern due to the negative P/E ratio and lack of dividend yield. The absence of earnings call and corporate events data limits further insights.

Compumedics Limited Business Overview & Revenue Model

Company Description

Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Okti; Grael PSG; Grael DC; Somfit/Somfit Pro, a wearable device; TCM5 FLEX Transcutaneous monitor; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, and persyst software products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.

How the Company Makes Money

Compumedics generates revenue through the sale of its proprietary medical devices and software solutions across various sectors, notably sleep medicine and neurology. Key revenue streams include direct sales of diagnostic equipment to hospitals, clinics, and sleep laboratories, as well as recurring revenue from software licensing and maintenance services. The company also benefits from partnerships with healthcare institutions and distributors, which expand its market reach and facilitate access to international markets. Additionally, Compumedics engages in research and development collaborations that can lead to new product innovations and revenue opportunities.

Compumedics Limited Financial Statement Overview

Summary

Compumedics Limited exhibits a mixed financial performance. While revenue growth is promising at 8.99%, profitability is a concern with a negative net profit margin of -2.49% and a low EBIT margin of 1.40%. The balance sheet shows moderate stability with a manageable debt-to-equity ratio of 0.64, but the negative return on equity of -5.83% indicates challenges in generating shareholder returns. Cash flow is a significant issue, with a negative free cash flow growth rate of -129.75%, reflecting poor cash management. Overall, the company needs to address profitability and cash flow issues to improve its financial health.

Income Statement

Compumedics Limited shows a mixed performance in its income statement. The company has achieved a positive revenue growth rate of 8.99% in the latest year, indicating an upward trend in sales. However, profitability remains a concern with a negative net profit margin of -2.49% and a low EBIT margin of 1.40%. The gross profit margin is relatively healthy at 60.71%, suggesting efficient production processes. Overall, while revenue is growing, the company struggles with profitability, which impacts its income statement score.

Balance Sheet

The balance sheet of Compumedics Limited reflects moderate financial stability. The debt-to-equity ratio stands at 0.64, indicating a manageable level of leverage. However, the return on equity is negative at -5.83%, highlighting challenges in generating returns for shareholders. The equity ratio is not explicitly provided, but the company's equity position appears stable relative to its assets. The balance sheet score reflects a balance between manageable debt levels and the need for improved profitability.

Cash Flow

Cash flow analysis reveals areas of concern for Compumedics Limited. The free cash flow growth rate is significantly negative at -129.75%, indicating cash flow challenges. The operating cash flow to net income ratio is low at 0.02, suggesting limited cash generation relative to net income. However, the free cash flow to net income ratio is relatively better at 0.69, indicating some ability to convert earnings into cash. Overall, the cash flow score reflects the need for improved cash management and generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	51.04M	51.04M	49.72M	42.41M	37.76M	35.74M
Gross Profit	30.99M	30.99M	26.07M	21.59M	19.32M	19.16M
EBITDA	1.94M	1.94M	2.79M	-5.05M	3.31M	2.56M
Net Income	-1.27M	-1.27M	-338.00K	-6.12M	1.36M	998.00K
Balance Sheet
Total Assets	54.39M	54.39M	40.36M	41.18M	41.71M	38.55M
Cash, Cash Equivalents and Short-Term Investments	2.69M	2.69M	1.89M	3.80M	7.29M	6.77M
Total Debt	13.88M	13.88M	8.58M	9.47M	6.55M	5.82M
Total Liabilities	32.57M	32.57M	22.15M	22.89M	18.12M	16.39M
Stockholders Equity	21.82M	21.82M	18.21M	18.29M	23.59M	22.16M
Cash Flow
Free Cash Flow	467.00K	467.00K	-986.00K	-4.36M	302.00K	-230.00K
Operating Cash Flow	681.00K	681.00K	2.00M	49.00K	3.29M	1.32M
Investing Cash Flow	-7.35M	-7.37M	-2.99M	-4.41M	-2.98M	-1.55M
Financing Cash Flow	6.10M	6.10M	-1.49M	-1.00M	1.61M	-179.00K

Compumedics Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMP, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.30, and above the 200-day MA of 0.29, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 64.22 is Neutral, neither overbought nor oversold. The STOCH value of 95.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CMP.

Compumedics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SOM	60 Neutral	$185.46M	―	-7.26%	―	21.65%	81.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CMP	50 Neutral	AU$72.08M	―	-6.35%	―	2.23%	-263.16%
CBL	47 Neutral	AU$14.49M	―	-103.74%	―	14.84%	39.64%
IPD	46 Neutral	$89.59M	―	-74.00%	―	23.31%	-17.35%
EMV	44 Neutral	AU$166.81M	―	-70.55%	―	―	-257.32%
CYC	42 Neutral	AU$81.13M	―	-31.98%	―	34.20%	-23.90%

Compumedics Limited Corporate Events

Compumedics Expands into Pharmaceutical Clinical Trials with Somfit Sales

Compumedics Limited has announced significant sales of its Somfit devices to major pharmaceutical and clinical research organizations in the USA and Europe, with revenues nearing $2 million. These sales mark a strategic expansion into the pharmaceutical clinical trial market, showcasing Somfit’s advanced capabilities in sleep monitoring and its potential beyond traditional home sleep testing. The contracts underscore the growing importance of sleep data in drug trials and highlight Compumedics’ commitment to diversifying its global business and exploring new growth avenues.

Compumedics Secures $24M Distribution Agreements in China

Compumedics Limited has signed two new 4-year distribution agreements in China, valued at A$24.4 million, with long-term partners. These agreements, which include a minimum 10% annual growth commitment, aim to strengthen Compumedics’ presence in Northern and Eastern China, focusing on sleep diagnostics and neurology. This strategic move is part of Compumedics’ broader effort to diversify and stabilize its revenue streams geographically and across product lines, positioning the company for sustained growth in key international markets, particularly in Asia.

Compumedics Limited Reports Record Sales and Strategic Growth in FY25

Compumedics Limited has announced a record-breaking fiscal year 2025, characterized by a 22% increase in sales orders and a return to profitability. The company’s strategic focus on the US market and SaaS platforms has driven significant growth, with US sales orders up by 115% and SaaS orders increasing by 49%. Looking ahead, Compumedics aims to scale its business model with new product launches and recurring revenue streams, projecting a revenue of at least $70 million and an EBITDA of approximately $9 million for FY26. The launch of the disposable Somfit in the US and the expansion of the MEG systems into the pediatric market are expected to further enhance the company’s market position and revenue potential.

Compumedics Adjusts FY25 Financial Guidance and Confirms FY26 Outlook

Compumedics Limited announced a correction to its financial guidance for FY25, expecting sales orders to exceed $60 million, with reported revenues between $50 million and $55 million, which is below the previously advised $55 million. The company anticipates an EBITDA of about $3 million for FY25, down from the previously advised $5 million. Looking ahead, Compumedics confirms FY26 revenue guidance of at least $70 million, driven by the shipment of MEG orders, with an expected EBITDA of at least $9 million.

Compumedics Secures $1M Somfit Contract with Leading US CRO

Compumedics Limited has secured a significant contract worth $1 million for its Somfit device with a leading pharmaceutical Contract Research Organisation in the USA. This sale is part of Compumedics’ strategy to expand beyond the home sleep testing market into pharmaceutical clinical trials, leveraging Somfit’s ability to directly track brain signals for accurate sleep architecture analysis. The contract highlights the company’s strong growth in the USA, with sales orders reaching $12 million this year, a 130% increase from the previous year. Compumedics anticipates continued growth, projecting sales orders over $60 million for FY25, although revenue and EBITDA expectations have been adjusted due to the rapid business expansion.